HOME › DRUGS › ENFORTUMAB VEDOTIN
ACTIVE SUBSTANCE / INN

ENFORTUMAB VEDOTIN

Brand name(s): Padcev
EMA LISTED
AUTHORISED
Carcinoma, Transitional Cell;Urologic Neoplasms
ACTIVE SUBSTANCE
Enfortumab Vedotin
REGULATORS
EMA
SPONSORS / MAH
Astellas Pharma Europe B.V.
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
PadcevAstellas Pharma Europe B.V.Authorised13/04/2022Carcinoma, Transitional Cell;Urologic Neoplasms

FULL INTELLIGENCE ON ENFORTUMAB VEDOTIN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →